WebApr 13, 2024 · By Cecilia Brown - April 13, 2024. While first-line use of novel agents has improved outcomes for some patients with multiple myeloma (MM), novel agents did not significantly improve outcomes in patients with t (11;14), according to a recent study. Borja Puertas, MD, of the University Hospital of Salamanca, and colleagues conducted the … WebSep 19, 2024 · Multiple myeloma (MM) is the second most common hematological malignancy and is attributed to monoclonal proliferation of plasma cells in the bone marrow. ... Despite the incorporation of novel agents over the past few years, the underlying metabolic reprogramming through hypoxia and increased lactate enhances tumor growth …
Novel Agents in Multiple Myeloma : The Cancer Journal - LWW
WebMar 30, 2024 · Keywords: multiple myeloma; novel agents; relapse. Conflict of interest statement . Financial & competing interests disclosureThis work is supported in part by the CTSA Grant UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. This work is also supported in part by the Marion … WebNov 13, 2024 · Discussions and Conclusions: This review highlights the need for ongoing research into cost effectiveness of novel agents in multiple myeloma. In general, novel agents are considered cost effective, however; there were a relatively small number of papers ion this topic and conclusions should be drawn with caution regarding the cost ... how is hst calculated
Efficient Allocation of Novel Agents in Multiple Myeloma: A Work …
WebJan 7, 2009 · A therapeutic renaissance in the history of cancer therapy has been unfolding with the recent development of what has been termed the ‘novel agents’ for the treatment … WebThe therapeutic landscape of multiple myeloma (MM) has dramatically changed in the last 15 years with the advent of immunomodulatory drugs and proteasome inhibitors. … WebJan 7, 2009 · A therapeutic renaissance in the history of cancer therapy has been unfolding with the recent development of what has been termed the ‘novel agents’ for the treatment of multiple myeloma (MM). Less than a decade ago, MM therapy was in the doldrums and had been that way for decades. highland ny middle school